603 related articles for article (PubMed ID: 32786284)
21. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Hattori SI; Higshi-Kuwata N; Raghavaiah J; Das D; Bulut H; Davis DA; Takamatsu Y; Matsuda K; Takamune N; Kishimoto N; Okamura T; Misumi S; Yarchoan R; Maeda K; Ghosh AK; Mitsuya H
mBio; 2020 Aug; 11(4):. PubMed ID: 32820005
[TBL] [Abstract][Full Text] [Related]
22. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.
Kato F; Matsuyama S; Kawase M; Hishiki T; Katoh H; Takeda M
Microbiol Immunol; 2020 Sep; 64(9):635-639. PubMed ID: 32579258
[TBL] [Abstract][Full Text] [Related]
23. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.
Deng W; Xu Y; Kong Q; Xue J; Yu P; Liu J; Lv Q; Li F; Wei Q; Bao L
Signal Transduct Target Ther; 2020 May; 5(1):66. PubMed ID: 32385228
[No Abstract] [Full Text] [Related]
25. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
[TBL] [Abstract][Full Text] [Related]
26. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
27. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
28. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Riva L; Yuan S; Yin X; Martin-Sancho L; Matsunaga N; Pache L; Burgstaller-Muehlbacher S; De Jesus PD; Teriete P; Hull MV; Chang MW; Chan JF; Cao J; Poon VK; Herbert KM; Cheng K; Nguyen TH; Rubanov A; Pu Y; Nguyen C; Choi A; Rathnasinghe R; Schotsaert M; Miorin L; Dejosez M; Zwaka TP; Sit KY; Martinez-Sobrido L; Liu WC; White KM; Chapman ME; Lendy EK; Glynne RJ; Albrecht R; Ruppin E; Mesecar AD; Johnson JR; Benner C; Sun R; Schultz PG; Su AI; García-Sastre A; Chatterjee AK; Yuen KY; Chanda SK
Nature; 2020 Oct; 586(7827):113-119. PubMed ID: 32707573
[TBL] [Abstract][Full Text] [Related]
29. Imatinib is not a potent anti-SARS-CoV-2 drug.
Zhao H; Mendenhall M; Deininger MW
Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
[No Abstract] [Full Text] [Related]
30. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
Wang S; Li W; Hui H; Tiwari SK; Zhang Q; Croker BA; Rawlings S; Smith D; Carlin AF; Rana TM
EMBO J; 2020 Nov; 39(21):e106057. PubMed ID: 32944968
[TBL] [Abstract][Full Text] [Related]
31. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
[TBL] [Abstract][Full Text] [Related]
32. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.
Yuan S; Wang R; Chan JF; Zhang AJ; Cheng T; Chik KK; Ye ZW; Wang S; Lee AC; Jin L; Li H; Jin DY; Yuen KY; Sun H
Nat Microbiol; 2020 Nov; 5(11):1439-1448. PubMed ID: 33028965
[TBL] [Abstract][Full Text] [Related]
33. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).
Huang F; Li Y; Leung EL; Liu X; Liu K; Wang Q; Lan Y; Li X; Yu H; Cui L; Luo H; Luo L
Pharmacol Res; 2020 Aug; 158():104929. PubMed ID: 32442720
[TBL] [Abstract][Full Text] [Related]
34. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
Lima WG; Brito JCM; Overhage J; Nizer WSDC
Arch Virol; 2020 Aug; 165(8):1729-1737. PubMed ID: 32514689
[TBL] [Abstract][Full Text] [Related]
35. Fight against novel coronavirus: A perspective of medicinal chemists.
Amin SA; Jha T
Eur J Med Chem; 2020 Sep; 201():112559. PubMed ID: 32563814
[TBL] [Abstract][Full Text] [Related]
36. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG
J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630
[TBL] [Abstract][Full Text] [Related]
37. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
Dai W; Zhang B; Jiang XM; Su H; Li J; Zhao Y; Xie X; Jin Z; Peng J; Liu F; Li C; Li Y; Bai F; Wang H; Cheng X; Cen X; Hu S; Yang X; Wang J; Liu X; Xiao G; Jiang H; Rao Z; Zhang LK; Xu Y; Yang H; Liu H
Science; 2020 Jun; 368(6497):1331-1335. PubMed ID: 32321856
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 and the safety margins of cell-based biological medicinal products.
Modrof J; Kerschbaum A; Farcet MR; Niemeyer D; Corman VM; Kreil TR
Biologicals; 2020 Nov; 68():122-124. PubMed ID: 32891497
[TBL] [Abstract][Full Text] [Related]
40. Déjà vu: Stimulating open drug discovery for SARS-CoV-2.
Ekins S; Mottin M; Ramos PRPS; Sousa BKP; Neves BJ; Foil DH; Zorn KM; Braga RC; Coffee M; Southan C; Puhl AC; Andrade CH
Drug Discov Today; 2020 May; 25(5):928-941. PubMed ID: 32320852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]